Revenue: As of FY2026 Q1, the actual value is USD 1.352 M.EPS: As of FY2026 Q1, the actual value is USD -0.81.EBIT: As of FY2026 Q1, the actual value is USD -3.612 M.<h4>Segment Revenue</h4><ul><li>Diagnostic R&amp;D: Revenue was $1,131 for the three months ended March 31, 2026, compared to $0 for the same period in 2025, primarily from Department of Defense observational studies .</li><li>Laboratory Services: Revenue was $1,350,396 for the three months ended March 31, 2026, a decrease from $1,853,597 for the same period in 2025 .</li><li>Total Net Revenue: Total net revenue decreased by approximately 36% to $1.4 million for the three months ended March 31, 2026, from $1.9 million for the three months ended March 31, 2025, due to discontinuing certain unprofitable pathology services, partially offset by increased revenue from the CyPath® Lung diagnostic test .</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss: The company reported a net loss of approximately -$3.6 million for the three months ended March 31, 2026, compared to approximately -$2.7 million for the same period in 2025 .</li><li>Total Operating Expenses: Increased by 11% to approximately $5.0 million for the three months ended March 31, 2026, from $4.5 million for the same period in 2025 .<ul><li>Diagnostic R&amp;D Operating Expenses: -$683,747 for the three months ended March 31, 2026, an increase from -$505,739 for the same period in 2025 .</li><li>Laboratory Services Operating Expenses: -$1,832,592 for the three months ended March 31, 2026, a decrease from -$2,267,656 for the same period in 2025 .</li><li>General Corporate Activities Operating Expenses: -$2,452,164 for the three months ended March 31, 2026, an increase from -$1,707,341 for the same period in 2025 .</li><li>Direct Costs and Expenses: Decreased by 32% to $0.9 million for the three months ended March 31, 2026, from $1.4 million for the same period in 2025, due to strategic actions to streamline operations and reduce lab costs .</li><li>Research and Development Expenses: Decreased by 5% to approximately $349,000 for the three months ended March 31, 2026, from $367,000 for the same period in 2025, primarily due to lower compensation costs, benefits, and lab supplies .</li><li>Clinical Development Expenses: Increased by 141% to approximately $334,000 for the three months ended March 31, 2026, from $138,000 for the same period in 2025, mainly due to the commencement of a pivotal clinical trial .</li><li>Selling, General and Administrative Expenses: Increased by 32% to approximately $3.2 million for the three months ended March 31, 2026, from $2.5 million for the same period in 2025, primarily due to increased employee compensation for administrative and sales personnel to support CyPath® Lung sales growth .</li><li>Depreciation and Amortization: Decreased by 26% to $115,000 for the three months ended March 31, 2026, from $155,000 for the same period in 2025, primarily due to the termination of a financing lease .</li></ul></li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: -$3.2 million for the three months ended March 31, 2026, an increase from -$1.6 million for the same period in 2025, primarily due to a $970,000 rise in loss from operations, a $352,000 decrease related to stock compensation and depreciation, and a $318,000 increase in patient accounts receivables, partially offset by a $20,000 increase in accounts payable and accrued expenses .</li><li>Net Cash Used in Investing Activities: -$6,000 for the three months ended March 31, 2026, compared to -$51,000 for the same period in 2025, primarily for the purchase of computer and laboratory equipment .</li><li>Net Cash Used in Financing Activities: -$0.1 million for the three months ended March 31, 2026, compared to $1.0 million provided by financing activities for the same period in 2025, reflecting no capital raises in Q1 2026 versus additional capital raised in Q1 2025 .</li><li>Cash and Cash Equivalents: $3.0 million at March 31, 2026, and $1.7 million at May 4, 2026 .</li></ul><h4>Unique Metrics</h4><ul><li>CyPath® Lung Unit Sales Growth: Unit sales achieved 146% growth in the first quarter of 2026 compared to the first quarter of 2025 .</li><li>CyPath® Lung Testing Revenue: Increased approximately 114% to $361,000 for the three months ended March 31, 2026, from $169,000 for the same period in 2025 .</li><li>Accumulated Deficit: -$72.2 million as of March 31, 2026 .</li><li>Working Capital: Approximately $1.2 million as of March 31, 2026 .</li></ul><h4>Future Outlook and Strategy</h4><ul><li>Going Concern: Management has substantial doubt about the company’s ability to continue as a going concern for at least twelve months, as current cash and anticipated revenue are expected to support operations only through June 2026 . Additional capital is required through various means to fund future operations and commercialization efforts .</li><li>Core Business Focus: bioAffinity Technologies, Inc. is developing noninvasive diagnostics for early-stage lung cancer and other lung diseases using flow cytometry and AI-driven automated analysis, with its subsidiary Precision Pathology Laboratory Services, LLC (PPLS) offering the CyPath® Lung diagnostic test .</li><li>Therapeutic Development: Through its subsidiary OncoSelect® Therapeutics, LLC, the company is advancing novel cancer therapeutic approaches that specifically target cancer cells and intends to seek strategic partners for development .</li><li>Clinical Trials: In March 2026, the company enrolled its first patient in a pivotal clinical trial (NCT07168993) for CyPath® Lung, supported by the John P. Murtha Cancer Center Research Program .</li></ul>

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 1.352 M